市場調查報告書
商品編碼
1541643
2024-2032 年按營養素類型(碳水化合物、脂質乳液、單劑量氨基酸溶液、微量元素、維生素和礦物質)、最終用戶(醫院、診所等)和地區分類的腸外營養市場報告Parenteral Nutrition Market Report by Nutrient Type (Carbohydrates, Lipid Emulsion, Single Dose Amino Acid Solution, Trace Elements, Vitamins and Minerals), End User (Hospitals, Clinics, and Others), and Region 2024-2032 |
IMARC Group年全球腸外營養市場規模達72億美元。
腸外營養 (PN) 或靜脈餵食提供液體營養物質,如脂肪、蛋白質、維生素、礦物質、碳水化合物和電解質。它是專門營養治療的一部分,為無法利用胃腸道的患者提供營養支持。它有助於預防營養不良並保持能量、水分和力量水平。因此,它被廣泛用於患有癌症、克隆氏症、短腸症候群、缺血性腸病和腸功能異常的患者。
營養不良盛行率上升、出生率上升和早產增加是推動全球營養需求的主要因素。此外,患有氣喘、白血病、結核病、支氣管炎、水痘和貧血等兒科疾病的人數顯著增加。再加上相對更容易患慢性病的老年人口不斷增加,也對 PN 產品的需求產生了正面影響。此外,速食消費的成長導致高血壓、糖尿病、肥胖和其他代謝紊亂等非傳染性疾病的發生率不斷增加。再加上肝功能不全、腎功能不全和蛋白質能量營養不良的發生率不斷上升,富含羊酸和腸外產品的消費量也增加。 PN 的顯著改進進一步推動了市場,例如脂肪乳劑最佳化和間接量熱法的利用。其他一些因素,例如多個國家的管理機構和私人實體對醫療保健行業整體發展的支出增加以及醫療保健行業擴大採用 PN 產品,預計將加強全球市場的成長。
The global parenteral nutrition market size reached US$ 7.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.9% during 2024-2032.
Parenteral nutrition (PN), or intravenous feeding, offers liquid nutrients like fats, proteins, vitamins, minerals, carbohydrates, and electrolytes. It is a part of specialized nutritional therapy that providing nutritional support to patients who are unable to utilize their gastrointestinal tract. It aids in preventing malnutrition and maintaining energy, hydration, and strength levels. As a result, it is widely used among patients who are suffering from cancer, Crohn's disease, short bowel syndrome, ischemic bowel disease, and abnormal bowel function.
The rising prevalence of malnutrition, growing natality rate, and increasing premature births are among the primary factors catalyzing the demand for PN around the world. Moreover, there is a considerable rise in the number of individuals experiencing pediatric disorders, such as asthma, leukemia, tuberculosis, bronchitis, chickenpox, and anemia. This, along with the rising geriatric population, which is relatively more prone to chronic diseases, is also influencing the demand for PN products positively. Furthermore, the growing consumption of fast food has resulted in the growing instances of non-communicable diseases like hypertension, diabetes, obesity, and other metabolic disorders. This, in confluence with the rising incidences of hepatic insufficiency, renal insufficiency and protein-energy malnutrition, is increasing the consumption of amnio acid-rich and parenteral products. The market is further driven by significant improvements in the PN, such as lipid emulsions optimizations and utilization of indirect calorimetry. Some of the other factors, such as increasing expenditure on the overall development of the healthcare sector by the governing agencies and private entities of several countries and rising adoption of PN products by the healthcare sector, are anticipated to strengthen the market growth across the globe.
IMARC Group provides an analysis of the key trends in each sub-segment of the global parenteral nutrition market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on nutrient type and end user.
Carbohydrates
Lipid Emulsion
Single Dose Amino Acid Solution
Trace Elements
Vitamins and Minerals
Hospitals
Clinics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aculife Healthcare Private Limited, B. Braun Melsungen AG, Baxter International Inc., Fresenius SE & Co. KGaA, Grifols S.A., Otsuka Pharmaceutical Factory Inc., Pfizer Inc. and Servona GmbH.